CD40 and neoplasm: Besides stimulation of CTL responses, agonistic anti-CD40 antibodies are known for targeting CD40+ tumor blood vessels, hereby enhancing tumor neoangiogenesis, which could give a pro-tumorigenic result [91, 92].